You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Population Pharmacokinetics of Tigecycline in Critically Ill Patients with Severe Infections
|
|---|---|
| Published in |
Antimicrobial Agents and Chemotherapy, July 2017
|
| DOI | 10.1128/aac.00345-17 |
| Pubmed ID | |
| Authors |
Jiao Xie, Jason A. Roberts, Abdulaziz S. Alobaid, Claire Roger, Yan Wang, Qianting Yang, Jinyao Sun, Haiyan Dong, Xue Wang, Jianfeng Xing, Jeffrey Lipman, Yalin Dong |
| Abstract |
Objectives: We sought to describe the population pharmacokinetics of tigecycline in critically ill patients and describe optimized dosing regimens of tigecycline for different bacterial infections.Methods: This prospective study included ten critically ill patients given a standard dose of tigecycline. Blood samples were collected during one dosing interval and analyzed using validated chromatography. Population pharmacokinetics and Monte Carlo dosing simulations were undertaken using Pmetrics. Three target exposures, ratios of 24h area under the curve to minimum inhibitory concentrations (AUC0-24/MIC), were evaluated (≥17.9 for skin infections, ≥6.96 for intraabdominal infections, ≥4.5 for hospital-acquired pneumonia).Results: The median age, total body weight and body mass index (BMI) were 67 years, 69.1 kg and 24.7 kg/m(2), respectively. A two-compartment linear model best described the time course of tigecycline concentrations. The mean±SD parameter estimates from the final model were clearance 7.50±1.11 L/h, volume of central compartment 72.50±21.18 L, rate constant for tigecycline distribution from the central to peripheral compartment 0.31±0.16 h(-1) and from the peripheral to central compartment 0.29±0.30 h(-1) A larger BMI was associated with increased CL of tigecycline. Licensed doses were found to be sufficient for Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, and Methicillin-resistant Staphylococcus aureus for an AUC0-24/MIC target of 4.5 or 6.96. For a therapeutic target of 17.9, an increase tigecycline dose is required, especially for patients with higher BMI.Conclusion: Dosing requirements of tigecycline differ with indication, pathogen susceptibility and potentially with patient BMI. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 14% |
| Australia | 1 | 14% |
| Spain | 1 | 14% |
| Unknown | 4 | 57% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 86% |
| Scientists | 1 | 14% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 59 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 14% |
| Student > Master | 8 | 14% |
| Other | 6 | 10% |
| Student > Bachelor | 6 | 10% |
| Student > Ph. D. Student | 6 | 10% |
| Other | 14 | 24% |
| Unknown | 11 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 25% |
| Medicine and Dentistry | 10 | 17% |
| Immunology and Microbiology | 5 | 8% |
| Agricultural and Biological Sciences | 2 | 3% |
| Business, Management and Accounting | 1 | 2% |
| Other | 6 | 10% |
| Unknown | 20 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2023.
All research outputs
#8,264,793
of 25,382,440 outputs
Outputs from Antimicrobial Agents and Chemotherapy
#7,296
of 15,580 outputs
Outputs of similar age
#121,744
of 327,041 outputs
Outputs of similar age from Antimicrobial Agents and Chemotherapy
#194
of 250 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one has received more attention than most of these and is in the 66th percentile.
So far Altmetric has tracked 15,580 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,041 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 250 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.